4-Methylmorpholine → 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one

HRID 1162285ノート

反応式

HRID 1162285 の反応式
ClC1[CH:7]=[CH:6][C:5]([NH:8][C:9](=[O:22])[NH:10][CH:11]([CH2:15]C2C=CC=CC=2)[C:12](O)=O)=[CH:4][CH:3]=1.C1C=C[C:26]2N(O)N=[N:29][C:27]=2C=1.CC[N:35]=C=NCCCN(C)C.CN1CCOCC1>CN(C=O)C>[CH3:26][C:27]1[N:10]2[C:9](=[O:22])[N:8]([CH:5]3[CH2:4][CH2:3][NH:35][CH2:7][CH2:6]3)[CH2:12][C:11]2=[CH:15][N:29]=1

参加物

6

反応物 4

HCID 79724-MethylmorpholineHCID 159081-Ethyl-3-(3'-dimethylaminopropyl)carbodiimideHCID 757711-HydroxybenzotriazoleHCID 29747892-(N'-(4-chlorophenyl)ureido)-3-phenylpropanoic acid

生成物 1

HCID 230840155-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one収率 99.5%

試薬・触媒・溶媒 1

HCID 6228Dimethylformamide溶媒

実験手順

To a solution of 2-(N′-(4-chlorophenyl)ureido)-3-phenylpropanoic acid (0.16 g) obtained in Example 1b) and HOBt (0.12 g) in DMF (10 ml) was added WSC (0.14 g), and the reaction mixture was mixed at room temperature for 15 minutes. Then, 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one (0.11 g) obtained in Reference Example 1 and N-methylmorpholine (0.08 ml) were added thereto. The reaction mixture was mixed at room temperature for 15 hours, and then the solvent was distilled off under reduced pressure. The residue was dissolved in ethyl acetate, washed with an aqueous sodium hydrogen carbonate solution and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure and the residue was purified with silica gel column (ethyl acetate to ethyl acetate/methanol=10/1). The product was washed with diethyl ether to obtain the title compound as colorless powder (0.13 g, 50%).

後処理

  1. additionthe reaction mixture was mixed at room temperature for 15 minutes

出典と根拠

ORDレコード
ord-ecf8ae63a38846658d2af4150219f67d
出典データセット
uspto-grants-2010_10
特許番号
US07820673B2

反応ノート

読み込み中…